Highly Sensitive Antibodies and Conjugates for Drugs of Abuse Detection

Drug abuse has been a persistent and long-standing global public health concern. The global rise of illicit drug use has resulted in the increased demand for drugs of abuse monitoring in law enforcement, the workplace, healthcare settings, and rehabilitation centers. Immunodiagnostic testing developed with premium quality raw materials enables the specific detection of drugs and their metabolites in biological fluids including urine and saliva. At Creative Diagnostics, we offer high-quality drugs of abuse antibodies and conjugates to meet your needs. Our extensive catalog provides antibodies combined with drug conjugates that can be used for ELISA or lateral flow detection.

Lateral Flow Immunochromatographic Assays for Drugs of Abuse Detection

The LFIA, also known as a lateral flow device, immunochromatographic assay, or lateral flow assay (LFA), is an effective point-of-care test (POCT). The principle of an LFA is based on the movement of a liquid sample through a strip with attached molecules that interact with the analyte, providing a signal that can be visually detected. The signal intensity is inversely proportional to the concentration of the target molecule in the sample. The LFIA follows the same principles as competitive enzyme-linked immunosorbent assays (cELISA). The T line contains the target molecules fixed. In the absence of the target molecule in the sample, unbound antibodies coupled with NP (Abs-NP) will bind to these target molecules fixed on the T line, resulting in visible coloration. Conversely, when the target molecule is present in the sample, it binds to the Abs-NP and stops their binding to the target molecule fixed on the T line, so no visual coloration will appear in the T line, or it will show some colors, but the signal is lower if an analyte is present.

Fig. 1 Competitive immunochromatographic test (Qriouet Z, et al. 2021)